A library of 17 C1-single and C1/C20-double modified salinomycin analogs was screened to identify compounds with improved activity against breast cancer stem cells.
[Biomedicine & Pharmacotherapy]
6445212 5FNTNFTC items 1 apa default asc 1
Urbaniak, A., Reed, M. R., Fil, D., Moorjani, A., Heflin, S., Antoszczak, M., Sulik, M., Huczyński, A., Kupsik, M., Eoff, R. L., MacNicol, M. C., Chambers, T. C., & MacNicol, A. M. (2021). Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models. Biomedicine & Pharmacotherapy, 141, 111815. https://doi.org/10.1016/j.biopha.2021.111815 Cite
Through investigating cellular functions including cell proliferation and stem cell features, it was demonstrated that hypoxic cancer-associated fibroblasts exosomes transferred circHIF1A into breast cancer cells, which played an important role in cancer stem cell properties sponging miR-580-5p by regulating CD44 expression.
[Cell Death Discovery]
6445212 PJFAZ3D4 items 1 apa default asc 1
Circulating tumor cells enumeration at initiation of endocrine therapy (ET), and at early and following time points was prognostic in ER-positive metastatic breast cancer starting second-line or later ET.
[npj Breast Cancer]
6445212 ZSJ6YSVL items 1 apa default asc 1
A large cohort of chemotherapy-naïve triple-negative breast cancer (TNBC), clinicopathologic features, deconvoluted RNA immune signatures, and intraepithelial and stromal TIME were identified in subsets of PD-L1+ and PD-L1- TNBC.
[Clinical Cancer Research]
6445218 X2QZKX4A items 1 apa default asc 1
Carter, J. M., Polley, M.-Y. C., Leon-Ferre, R. A., Sinnwell, J., Thompson, K. J., Wang, X., Ma, Y., Zahrieh, D., Kachergus, J. M., Solanki, M., Boughey, J. C., Liu, M. C., Ingle, J. N., Kalari, K. R., Couch, F. J., Thompson, E. A., & Goetz, M. P. (2021). Characteristics and spatially-defined immune (micro)landscapes of early-stage PD-L1-positive triple-negative breast cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-21-0343 Cite
The authors investigated the metabolic vulnerabilities of TNBC, particularly those metabolic perturbations that increased mitochondrial apoptotic priming and sensitivity to BH3 mimetics.
6445212 MLUTDU4F items 1 apa default asc 1
DDR1 knockdown and DDR1 pharmacological inhibitor decreased cell growth and inhibited cell cycle progression in breast cancer cell lines, while enhanced the sensitivity of PIK3CA/AKT1 mutant cells to palbociclib.
6445212 XQRED8QH items 1 apa default asc 1
Scientists created homogeneous antibody-drug conjugates containing two distinct payloads that showed HER2-specific cell killing potency, desirable pharmacokinetic profiles, minimal inflammatory response, and marginal toxicity at therapeutic doses.
6445212 E9337S4D items 1 apa default asc 1
The authors highlight the association of several long noncoding RNAs in TNBC progression and treatment, along with their possible functions and mechanisms.
[Journal of Cellular Physiology]
6445212 3B7DYBYG items 1 apa default asc 1
Byondis B.V. announced positive results from the Phase III TULIP® study. The trial compared the efficacy and safety of the company’s antibody-drug conjugate [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer.
6445212 nan items 1 apa default asc 1
Researchers showed that matrix stiffening rewired glutamine metabolism to promote microtubules (MT) glutamylation and force MT stabilization, thereby promoting cell invasion.
6445212 2FH2BFHT items 1 apa default asc 1
The authors studied endocrine immune related adverse events from seven clinical trials across six cancers where atezolizumab was combined with chemotherapies and compared to standard of care.
6445218 DTJ4GQFX items 1 apa default asc 1
Khan, Z., Hammer, C., Carroll, J., Di Nucci, F., Acosta, S. L., Maiya, V., Bhangale, T., Hunkapiller, J., Mellman, I., Albert, M. L., McCarthy, M. I., & Chandler, G. S. (2021). Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade. Nature Communications, 12(1), 3355. https://doi.org/10.1038/s41467-021-23661-4 Cite